Melanotan I vs Melanotan II: Linear vs Cyclic Alpha-MSH Analogs

Two compounds, named almost identically, built from the same parent hormone — and not two grades of the same thing. Melanotan I and melanotan II are separate structural answers to one chemistry problem, and the gap between them is wider than the naming suggests. Both are supplied for research use only, and nothing below is a statement about use in people. But if you're comparing melanotan I vs melanotan II structure on a certificate of analysis, the difference between a linear thirteen-residue chain and a cyclic seven-residue macrocycle drives almost everything downstream: molecular weight, reported stability, receptor coverage, and how the molecule holds its shape.

Where Both Molecules Start: Alpha-MSH and the Melanocortin Family

Before either analog existed, there was a short natural hormone the body makes and then takes apart within minutes: alpha-melanocyte-stimulating hormone, usually written alpha-MSH. Both melanotan compounds are attempts to build a sturdier version of it.

Alpha-MSH is a tridecapeptide — thirteen amino acids — with the sequence Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2. It is cut from ACTH(1-13), which is itself cut from a larger precursor protein called proopiomelanocortin, or POMC.

It acts as a non-selective full agonist across most of the melanocortin receptor family, with reported binding constants of Ki = 0.230 nM at MC1, 31.5 nM at MC3, 900 nM at MC4 and 7160 nM at MC5. MC2 is the exception — that one is reserved for ACTH. Note the spread across the other four: nearly a thousand-fold between the tightest and the loosest.

The Problem Chemists Set Out to Solve

The native hormone has a short working life. The medicinal-chemistry literature describes linear melanotropins like alpha-MSH as biologically unstable, with a half-life on the order of minutes, degraded readily by enzymes in serum and in the gut. For a laboratory reagent that's a real constraint — the molecule you add isn't the molecule still present an hour later.

Two liabilities sit right in the sequence. Position 4 is methionine, whose sulfur atom oxidizes easily. And the backbone is all L-amino acids, which is exactly what proteases evolved to recognize and clip.

The Shared Core: His-Phe-Arg-Trp

Strip either molecule down to what it cannot lose, and the same four residues survive in both.

His-Phe-Arg-Trp is the minimal sequence capable of activating all the human melanocortin receptors — the shortest fragment that still works, and therefore the non-negotiable unit of any melanocortin analog. Everything else in these molecules exists either to protect that core or to hold it in a favorable geometry.

How much of the binding signal those residues carry has been measured directly, by replacing each position with alanine and watching potency fall. In the linear analog NDP-MSH, substituting position 7 (D-Phe) costs 180- to 2370-fold potency across receptors, and position 9 (Trp) costs 180- to 2120-fold.

The Same Core Behaves Differently in Different Frames

Here's where it gets complicated. The same alanine scan shows that Glu5 substitution costs 1560-fold potency at mMC1R in native alpha-MSH, but is nearly free in NDP-MSH — equipotent, or under a five-fold shift. Arg8 splits the same way: a 200- to 470-fold loss in alpha-MSH against only 6- to 29-fold in NDP-MSH. "Same core" does not mean "same structure-activity relationship." The scaffold built around the core redistributes which residues actually carry the binding signal, so findings from one analog don't transfer to the other unchecked.

Melanotan I: The Linear Route

Melanotan I is the conservative answer — keep the entire molecule, and change about two atoms' worth of chemistry.

Also called afamelanotide or NDP-MSH, it is formally [Nle4,D-Phe7]-alpha-MSH: Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2, formula C78H111N21O19, molar mass 1646.87 g/mol. Line it up against the parent hormone and the backbone is identical — same thirteen positions, same order, two residues swapped.

What Each Substitution Fixes

Norleucine at position 4 is methionine with the sulfur removed. The side chain keeps a similar length and shape, so the molecule still fits where it needs to, but the oxidation liability is gone — a targeted repair rather than a redesign. The same substitution logic appears in GHRH analog design, where single-residue swaps at a vulnerable position buy stability without disturbing recognition.

Position 7 is a different kind of change. Inverting the stereochemistry from L-phenylalanine to D-phenylalanine doesn't change the atoms at all — only their arrangement in space. Proteases are stereospecific, so a D-residue at a cleavage site is far harder for them to process. In the published work the inversion improved both potency and stability, an unusually clean result for a single-center change. Chirality being the whole point, it's also what analytical labs verify on finished material — polarimetry is one of the standard checks.

What It Bought

The payoff is a molecule whose receptor binding lasts longer than that of alpha-MSH, attributed in part to resistance to immediate degradation by serum or proteolytic enzymes. Receptor coverage stayed where the parent hormone left it: predominantly MC1R, with activity at MC3, MC4 and MC5.

One naming caveat matters here. Afamelanotide is an INN — an approved nonproprietary name attached to a specific prescription product. Research-grade material sharing that sequence is not the FDA-approved pharmaceutical of the same name, is not made under the same quality system, and is not interchangeable with it.

Melanotan II: The Cyclic Route

Melanotan II takes the aggressive path — discard most of the backbone, then staple what remains into a ring.

Its structure is written Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, a cyclic (2-7) peptide with formula C50H69N15O9 and a molecular weight of 1024.20 g/mol — roughly 600 daltons lighter than melanotan I. Six residues of the parent backbone are simply absent: the Ser-Tyr-Ser opening and the Gly-Pro-Val tail are gone, leaving the core plus a scaffold to hold it.

How the Ring Is Closed

The macrocycle is built during synthesis: the epsilon-amino group of lysine and the gamma-carboxy group of aspartic acid have their orthogonal protection removed, then carbodiimide-mediated lactamization joins them into an amide bond.

Worth being precise about the ring: it's a side-chain-to-side-chain staple, not a head-to-tail circle. The termini stay free and capped while two side chains bond across the sequence. Length is a deliberate lever in peptide design generally — chain length shows up as a design variable in growth-hormone secretagogues too — but here truncation and cyclization work together.

What the Ring Bought

Stability is the headline. The same review that calls native alpha-MSH unstable at a half-life of minutes describes the cyclized compound as biologically stable, with a reported half-life of 1 to 2 days — three orders of magnitude, from one structural intervention. That source also notes the constrained analog crosses the blood-brain barrier, which matters structurally because the central melanocortin receptors are MC3 and MC4, not MC1.

Receptor coverage, though, didn't narrow. Melanotan II remains a non-selective agonist at MC1, MC3, MC4 and MC5, with melanogenesis associated with MC1R activation and its other documented pharmacology attributed to MC4R.

Linear vs Cyclic: What Conformational Constraint Actually Buys

The real difference isn't length. It's how much freedom each molecule has to be the wrong shape.

Pre-Organizing the Bound Conformation

Both alpha-MSH and NDP-MSH adopt a folded conformation that places the aromatic residues His6, Phe7 (or D-Phe7) and Trp9 on the same face in a beta-turn structure, with NMR work pointing to the His6-D-Phe7 pair as the center of that turn. The receptor binds the folded form.

A linear peptide in solution is constantly rearranging, and every time it approaches the receptor it has to find that beta-turn again out of a large population of shapes that don't bind. A lactam bridge removes the search: the ring holds the turn permanently, so the molecule arrives already in the productive conformation. It's the difference between a folding chair someone has already opened and one you unfold at the door.

What the Receptor Is Grabbing

Two kinds of contact have been proposed. An ionic interaction pairs the positively charged Arg8 with acidic residues in transmembrane helix 2 (Glu100) and helix 3 (Asp122, Asp126), while hydrophobic contacts form between the D-Phe7 and Trp9 side chains and surfaces on helices 4, 6 and 7. The beta-turn positions all three side chains correctly at once.

Measured Consequences

The constraint shows up in binding numbers. Lactam-bridged alpha-MSH macrocycles have been characterized with MC1R IC50 values ranging from 0.90 nM for a twelve-residue ring to 2.10 nM, with a six-residue ring at 1.77 nM. The same work reports that the six-residue lactam construct showed both higher MC1R binding affinity and a slower MC1R dissociation rate than the native alpha-MSH peptide — and a slower off-rate means longer occupancy per binding event, independent of how tightly the molecule binds in the first place.

Ring size turns out to be its own variable. In a matched preclinical distribution model, the smaller ring showed 1.86 times the tumor uptake of the larger at the two-hour timepoint, while renal uptake fell to 72.8% of the larger analog's value — with no loss of binding affinity from the truncation. Affinity held steady while distribution behavior shifted substantially.

Receptor Coverage: Why Neither Analog Is Selective

Both compounds engage four of the five melanocortin receptors. That's a limitation inherited from the parent hormone, not a design achievement.

Alpha-MSH is promiscuous across MC1, MC3, MC4 and MC5, and both analogs carry that forward. MC1R is the pigmentation-associated receptor; MC3R and MC4R are the central ones; MC5R is peripheral. A non-selective agonist engages all of them at once, which makes clean mechanistic interpretation harder in any experiment that doesn't isolate a single subtype. Selectivity has to be engineered deliberately — incretin analogs show the same principle, where mono- and dual-agonist designs differ by exactly this kind of structural targeting.

The field moved on accordingly, substituting conformationally constrained amino acids such as Tic or Aia into the core sequence to pull the receptor subtypes apart, and N-methylating cyclized backbones to improve oral bioavailability through stabilization of cis-peptide bonds. Both melanotan compounds are best understood as early waypoints in melanocortin medicinal chemistry rather than endpoints.

Two Very Different Regulatory Paths

Identical naming conventions, opposite outcomes. Afamelanotide was approved in the EU in January 2015 and by the US FDA in October 2019 for erythropoietic protoporphyria, designated first-in-class, and is prescription-only in the US, EU, UK, Canada and Australia. Its approved format is a slow-release implant: most of the compound is released within two days and none is detectable in plasma by the tenth — against a plasma half-life of roughly 30 minutes for the free peptide.

Melanotan II went the other direction. Development was abandoned in 2000, the compound never reached market, and unlicensed material circulating online is not legal to be sold for human usage in any jurisdiction.

For anyone sourcing either as a research material, the name on a vial tells you an intended sequence, not a provenance. Identity, purity, and counterion content on a certificate of analysis are what distinguish one batch from another.

Frequently Asked Questions

What is the actual structural difference between melanotan I and melanotan II?

Melanotan I keeps the full 13-residue alpha-MSH backbone and changes only two positions, so it stays a linear chain. Melanotan II keeps a seven-residue fragment built around the active core and closes it into a ring with a lactam bridge between an aspartate and a lysine side chain. The molecular weights tell the story: roughly 1647 g/mol against 1024 g/mol.

Why do both compounds contain a D-amino acid?

Position 7 in both analogs is D-phenylalanine rather than the L-phenylalanine found in native alpha-MSH. Proteases are stereospecific, so flipping one residue to the D configuration makes that bond much harder to clip. In published structure-activity work the inversion also improved receptor potency, which is why it carried over from the linear analog into the cyclic one.

Is afamelanotide the same thing as research-grade melanotan I?

No. Afamelanotide is an approved prescription medication manufactured under pharmaceutical quality systems and supplied in a specific controlled-release format. Research-grade material sharing the same peptide sequence is not the FDA-approved pharmaceutical product, is not manufactured to the same standard, and is supplied for laboratory work only.

Does cyclization always improve a peptide analog?

Not automatically. It raises metabolic stability and pre-organizes the bound conformation, but it also locks the molecule into one shape — and if that shape is slightly wrong for a given receptor, affinity drops rather than rises. In the lactam-bridge literature, ring size changed distribution behavior substantially while binding affinity stayed in the same nanomolar band.

Why is the His-Phe-Arg-Trp sequence so important?

It is the shortest fragment that still activates all the human melanocortin receptors, making it the minimum unit any melanocortin analog has to preserve. Everything else — the extra residues in melanotan I, the lactam bridge in melanotan II — exists to protect that core or hold it in a favorable geometry.

The Structural Bottom Line

Melanotan I and melanotan II are not two grades of the same compound. One is a linear thirteen-residue peptide; the other is a cyclic seven-residue macrocycle. What they genuinely share is a four-residue core and a parent hormone.

Melanotan I preserves the parent architecture and patches its two weakest points — the oxidizable methionine and the protease-readable L-Phe. Melanotan II throws the architecture away and immobilizes the core instead. The measured trade-offs between those strategies — minutes against days of reported stability, 1647 against 1024 daltons, a flexible backbone against a pre-organized beta-turn — make this pair one of the clearest illustrations in the melanocortin literature of what conformational constraint does to a peptide.

For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.

Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.